Postpartum Prescription of GLP-1 Drugs Has Increased Sharply, Study Finds
Postpartum Prescription of GLP-1 Drugs Has Increased Sharply, Study Finds
By mid-2024, the weight-loss drugs were prescribed for almost 2 percent of new mothers.
Read the full article on NY Times Health
Truth Analysis
Analysis Summary:
The article's claim about the increase in postpartum GLP-1 prescriptions is potentially plausible given the general trend of increased GLP-1RA usage, but the specific percentage (2% by mid-2024) is not directly verifiable from the provided sources. The article exhibits moderate bias through selective reporting, focusing on a specific trend without providing broader context or potential counterarguments.
Detailed Analysis:
- Claim: By mid-2024, the weight-loss drugs were prescribed for almost 2 percent of new mothers.
- Verification Source #1: Source 1 mentions the surge in interest in GLP-1RAs, spurred by semaglutide's approval for weight management in 2021, and discusses assessing GLP-1RA dispensing, but does not provide specific data on postpartum prescriptions or the 2% figure.
- Assessment: Unverified. While Source 1 confirms increased interest and dispensing of GLP-1RAs, it doesn't provide data to support the specific 2% claim. The claim is plausible given the trend, but lacks direct verification from the provided sources.
Supporting Evidence/Contradictions:
- Source 1: "Interest in these drugs has surged, spurred partly by the approval of semaglutide for weight management in 2021. Assessing GLP-1RA dispensing to..." This supports the general trend of increased GLP-1RA usage but doesn't verify the specific claim about postpartum prescriptions.